Celcuity Inc. reported a third-quarter net loss of $73.3 million, or $1.33 per share, compared to a $43.8 million loss in the prior-year period. The wider deficit reflects a $27.4 million surge in selling, general and administrative expenses driven by commercialization costs for REVTORPYK, which became commercially available on September 30, 2026. Total operating expenses reached $77.3 million as research and development spending also rose to $37.5 million. The company holds $642.7 million in cash and short-term investments, sufficient to fund operations through 2029. Additionally, Byron Robinson joined the executive team as Chief Strategy Officer. Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for solid tumors.
